Ranok Therapeutics, Pfizer team up on targeted protein degradation

By The Science Advisory Board staff writers

November 30, 2021 -- Ranok Therapeutics and Pfizer are teaming up to evaluate Ranok's chaperone-mediated protein degradation (CHAMP) platform technology on an undisclosed cancer target.

CHAMP takes advantage of the cellular chaperone network, which could potentially improve the technology's safety and efficacy due to the selective targeting of tumors versus other targeted protein degradation approaches, Ranok said.

Ranok received $40 million in series B financing in August 2021.

Financial details of the agreement were not disclosed.

Copyright © 2021 scienceboard.net
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here